文献速递前列腺癌

非区域淋巴结转移对转移性前列腺癌风险分层的重要性

Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
PubMed 文献 · BJU Int · 2018-06-13

该研究基于SEER数据库2004–2013年17 167例转移性前列腺癌患者,比较骨转移合并非区域淋巴结(NRLN)转移与单纯骨转移的预后。结果显示,骨+NRLN转移患者全因死亡和前列腺癌特异性死亡风险均显著高于单纯骨转移,提示NRLN转移应被视为高风险特征,现有「低/高瘤负荷」分层未涵盖此现象。

要点

  • 骨转移合并NRLN转移患者全因死亡风险显著高于单纯骨转移(HR 1.161)。
  • 骨+NRLN转移患者前列腺癌特异性死亡风险亦显著升高(subdistribution HR 1.149)。
  • 现有「低/高瘤负荷」分层未考虑NRLN转移,可能影响 aggressive 联合治疗的获益。

核心结论

  • 骨转移合并NRLN转移患者死亡风险显著高于单纯骨转移,NRLN转移应视为高风险特征。
  • 现有「低/高瘤负荷」治疗分层未涵盖NRLN转移现象,可能影响患者获得最大治疗获益。

研究设计与样本

  • 回顾性队列研究,数据来自SEER数据库2004–2013年诊断为转移性前列腺癌的17 167例患者。
  • 按转移部位分组:仅NRLN、仅骨、骨+NRLN、其他部位±骨/NRLN转移。
  • 采用多因素Cox回归和竞争风险回归比较全因死亡(ACM)和前列腺癌特异性死亡(PCSM)风险,并进行倾向评分匹配、landmark分析和补充分析。

主要发现

  • 63.1%的患者表现为仅骨转移,8.9%的患者同时存在骨和NRLN转移。
  • 多因素分析显示,骨+NRLN转移患者较单纯骨转移患者ACM风险显著升高(HR 1.161,95%CI 1.084–1.243;P<0.001)。
  • 骨+NRLN转移患者较单纯骨转移患者PCSM风险显著升高(subdistribution HR 1.149,95%CI 1.067–1.237;P<0.001)。
  • 限定生存≥6个月和≥12个月的landmark分析再次显示骨+NRLN转移患者ACM风险显著增加。
  • 1:1倾向评分匹配队列中,骨+NRLN组ACM(HR 1.202,95%CI 1.102–1.311;P<0.001)和PCSM(subdistribution HR 1.146,95%CI 1.044–1.259;P=0.004)风险仍更高。

临床怎么用

  • 在转移性前列腺癌风险分层中,应关注NRLN转移的存在,骨+NRLN转移提示更高死亡风险。
  • 现有基于「低/高瘤负荷」的分层可能低估骨+NRLN转移患者风险,需考虑更积极的联合治疗策略。

局限性

  • 研究为基于SEER数据库的回顾性分析,可能存在未测量混杂因素。
  • 原文未报告NRLN转移的详细定义、影像学确认方法及治疗信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the prognostic relevance of non-regional lymph node (NRLN) metastases presenting synchronously with bone metastases in metastatic prostate cancer (mPCa) for guiding treatment decisions based on oligometastatic definitions. PATIENTS AND METHODS: Patients diagnosed with mPCa between 2004 and 2013 were identified from the Surveillance, Epidemiology and End Results database and were grouped by metastatic sites into only NRLN, only bone, bone + NRLN and other sites ± bone/NRLN metastases. Multivariate Cox and competing risk regression analyses were performed to compare the risks of all-cause mortality (ACM) and prostate cancer-specific mortality (PCSM) associated with bone + NRLN metastases before and after propensity-score matching to patients with only bone metastases. This was complemented with landmark and supplementary analyses. RESULTS: Of 17 167 patients with mPCa identified, 63.1% presented with only bone metastases, while bone and NRLN metastases co-occurred in 8.9% of the cohort. On multivariate analyses, after adjusting for potential confounders (clinical and sociodemographic), patients with bone + NRLN metastases had a significantly higher risk of ACM (hazard ratio [HR] 1.161, 95% confidence interval [CI] 1.084-1.243; P < 0.001) and PCSM (subdistribution HR 1.149, 95% CI 1.067-1.237; P < 0.001) compared with patients with only bone metastases. Landmark analyses limited to survivors of ≥6 and ≥12 months again showed a significantly increased risk of ACM for patients presenting with bone + NRLN metastases compared with patients with only bone metastases. In a subsequent 1:1 propensity-score-matched cohort of patients with bone + NRLN metastases and only bone metastases, the bone + NRLN group had higher multivariate-adjusted hazard rates for ACM (HR 1.202, 95% CI 1.102-1.311; P < 0.001) and PCSM (subdistribution HR 1.146, 95% CI 1.044-1.259; P = 0.004). CONCLUSIONS: Patients with concomitant NRLN and bone metastases have a higher risk of death, NRLN and bone metastases therefore representing a high-risk feature, when compared with patients with bone metastases alone. The current therapeutic stratification of 'low-' vs 'high-volume' disease does not account for this phenomenon, and patients requiring aggressive combination therapy may not receive maximum therapeutic benefit as a consequence.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ali A, Hoyle A, Mistry H, et al. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer. BJU Int. 2018. PMID: 29777564. doi:10.1111/bju.14400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。